Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 100. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply1743
Environment and infectious diseases1289
A step forward in the journey towards hookworm vaccines928
Listeria monocytogenes: a rare, deadly cause of peritonitis678
Surge of cutaneous leishmaniasis in Pakistan601
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply598
Research in brief594
Research in brief491
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting402
Attention to skin-related neglected tropical diseases379
Infectious disease surveillance update376
Chronicling PEPFAR's work in Africa357
Ordinary people in extraordinary times325
Infectious disease surveillance update302
Promoting diversity and equity in publishing289
Entering a labyrinth of COVID-19 stories287
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7279
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria279
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations270
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect261
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study260
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges248
Adaora “Ada” Alise Adimora247
The superiority of bivalent over monovalent booster vaccines242
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum236
DNDi receives Dutch funding boost235
COVID-19 vaccination protects children and adolescents227
Can the USA return to pre-COVID-19 normal by July 4?225
Reflecting on lessons from the 2014–16 Ebola virus outbreak223
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis217
Bold measures to accelerate malaria elimination214
A patient with secondary syphilis following incomplete treatment of primary infection208
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations207
HIV vaccine trial failure205
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco204
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden191
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial191
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study186
Threat of HIV and tuberculosis drug resistance after US funding cuts184
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C172
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial171
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial171
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines168
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis167
Updated criteria for paediatric sepsis and septic shock166
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic166
The interplay between COVID-19 restrictions and vaccination166
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review163
Transitioning to endemicity with COVID-19 research160
The next chapter for Africa's genomic initiatives159
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1157
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom157
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin156
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study156
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study156
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial154
Measles immunity gaps and outbreak risk in a shifting landscape152
Mpox in people with past infection or a complete vaccination course: a global case series150
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation150
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study150
The importance of understanding the infectious microenvironment148
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2147
Supporting healthcare access for refugees and migrants146
History and evolution of tuberculosis and global health145
Assessment of experimental malaria vaccine induced protection in pre-exposed populations143
Election of Regional Director for the Western Pacific142
Severe influenza: is there a role for antiviral combinations?140
The implications of mpox breakthrough infections on future vaccination strategies140
Sizing the reservoirs of malaria transmission: the contribution of school-aged children135
Correction to Lancet Infect Dis 2021; 21: 962–74135
Emil Gotschlich133
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world131
Interplay of infection and vaccination in long-term protection from COVID-19131
Immune evasiveness of SARS-CoV-2 variants and vaccine selection130
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis129
Global cholera resurgence—a preventable tragedy129
Super-spreaders: a historical review128
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant127
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis125
Elisabeth Presterl—always looking forward124
WHO Pathogen X conference123
Addressing the shortage of cholera vaccines122
WHO's first global infection prevention and control report122
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms118
Malaria vaccine development in Mali: a step towards transmission-blocking strategies118
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5117
Correction to Lancet Infect Dis 2023; 23: e469117
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0116
Correction to Lancet Infect Dis 2021; 21: 629–36116
Research in brief115
Full-dose NSAIDs at the first sign of respiratory infection?113
Theresa Ochoa—staying on top of infectious diseases in Peru111
Infectious disease surveillance update110
Is combination antiviral therapy for influenza the optimal approach?108
Curing chronic hepatitis B virus infection102
Tuberculosis recovery in Georgia: implementing more by 24102
The response of mpox-associated inflammatory syndrome to steroid therapy101
Research in brief101
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86101
Vaccine and surveillance implications of dengue underdetection101
0.086621999740601